The molecular epidemiology of lung cancer

Simon D. Spivack, Michael J. Fasco, Vernon E. Walker, Laurence S. Kaminsky

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

One in ten tobacco smokers develops bronchogenic carcinoma over a lifetime. The study of susceptibility of an individual and a population to lung canter traditionally has been limited to the study of tobacco smoke dose and family history of cancer. New insights into lung carcinogenesis have made the study of molecular markers of risk possible in human populations in the emerging field of molecular epidemiology. This review summarizes data addressing the relationships of human lung cancer to polymorphisms of phase I procarcinogen-activating and phase II-deactivating enzymes and intermediate biomarkers of DNA mutation, such as DNA adducts, oncogene and tumor suppressor gene mutation, and polymorphisms. These parameters are reviewed as they relate to tobacco smoke exposure, procarcinogen metabolizing polymorphisms, and the presence of lung cancer. Problem areas in biomarker validation, such as cross-sectional data interpretation, tissue source, race, statistical power, and ethical implications are addressed.

Original languageEnglish (US)
Pages (from-to)319-365
Number of pages47
JournalCritical Reviews in Toxicology
Volume27
Issue number4
StatePublished - 1997
Externally publishedYes

Fingerprint

Molecular Epidemiology
Tobacco
Polymorphism
Lung Neoplasms
Biomarkers
Smoke
Genetic Suppression
Lung
DNA Adducts
Bronchogenic Carcinoma
Tumor Suppressor Genes
Oncogenes
Population
Tumors
Carcinogenesis
Genes
Tissue
Mutation
DNA
Enzymes

Keywords

  • Biomarkers
  • DNA adducts
  • Lung cancer
  • Oncogenes
  • Phase I metabolism
  • Phase II metabolism
  • Susceptibility
  • Tumor suppressor genes

ASJC Scopus subject areas

  • Toxicology

Cite this

Spivack, S. D., Fasco, M. J., Walker, V. E., & Kaminsky, L. S. (1997). The molecular epidemiology of lung cancer. Critical Reviews in Toxicology, 27(4), 319-365.

The molecular epidemiology of lung cancer. / Spivack, Simon D.; Fasco, Michael J.; Walker, Vernon E.; Kaminsky, Laurence S.

In: Critical Reviews in Toxicology, Vol. 27, No. 4, 1997, p. 319-365.

Research output: Contribution to journalArticle

Spivack, SD, Fasco, MJ, Walker, VE & Kaminsky, LS 1997, 'The molecular epidemiology of lung cancer', Critical Reviews in Toxicology, vol. 27, no. 4, pp. 319-365.
Spivack SD, Fasco MJ, Walker VE, Kaminsky LS. The molecular epidemiology of lung cancer. Critical Reviews in Toxicology. 1997;27(4):319-365.
Spivack, Simon D. ; Fasco, Michael J. ; Walker, Vernon E. ; Kaminsky, Laurence S. / The molecular epidemiology of lung cancer. In: Critical Reviews in Toxicology. 1997 ; Vol. 27, No. 4. pp. 319-365.
@article{680af22f35c7483ca6dfe716a2a2849e,
title = "The molecular epidemiology of lung cancer",
abstract = "One in ten tobacco smokers develops bronchogenic carcinoma over a lifetime. The study of susceptibility of an individual and a population to lung canter traditionally has been limited to the study of tobacco smoke dose and family history of cancer. New insights into lung carcinogenesis have made the study of molecular markers of risk possible in human populations in the emerging field of molecular epidemiology. This review summarizes data addressing the relationships of human lung cancer to polymorphisms of phase I procarcinogen-activating and phase II-deactivating enzymes and intermediate biomarkers of DNA mutation, such as DNA adducts, oncogene and tumor suppressor gene mutation, and polymorphisms. These parameters are reviewed as they relate to tobacco smoke exposure, procarcinogen metabolizing polymorphisms, and the presence of lung cancer. Problem areas in biomarker validation, such as cross-sectional data interpretation, tissue source, race, statistical power, and ethical implications are addressed.",
keywords = "Biomarkers, DNA adducts, Lung cancer, Oncogenes, Phase I metabolism, Phase II metabolism, Susceptibility, Tumor suppressor genes",
author = "Spivack, {Simon D.} and Fasco, {Michael J.} and Walker, {Vernon E.} and Kaminsky, {Laurence S.}",
year = "1997",
language = "English (US)",
volume = "27",
pages = "319--365",
journal = "Critical Reviews in Toxicology",
issn = "1040-8444",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The molecular epidemiology of lung cancer

AU - Spivack, Simon D.

AU - Fasco, Michael J.

AU - Walker, Vernon E.

AU - Kaminsky, Laurence S.

PY - 1997

Y1 - 1997

N2 - One in ten tobacco smokers develops bronchogenic carcinoma over a lifetime. The study of susceptibility of an individual and a population to lung canter traditionally has been limited to the study of tobacco smoke dose and family history of cancer. New insights into lung carcinogenesis have made the study of molecular markers of risk possible in human populations in the emerging field of molecular epidemiology. This review summarizes data addressing the relationships of human lung cancer to polymorphisms of phase I procarcinogen-activating and phase II-deactivating enzymes and intermediate biomarkers of DNA mutation, such as DNA adducts, oncogene and tumor suppressor gene mutation, and polymorphisms. These parameters are reviewed as they relate to tobacco smoke exposure, procarcinogen metabolizing polymorphisms, and the presence of lung cancer. Problem areas in biomarker validation, such as cross-sectional data interpretation, tissue source, race, statistical power, and ethical implications are addressed.

AB - One in ten tobacco smokers develops bronchogenic carcinoma over a lifetime. The study of susceptibility of an individual and a population to lung canter traditionally has been limited to the study of tobacco smoke dose and family history of cancer. New insights into lung carcinogenesis have made the study of molecular markers of risk possible in human populations in the emerging field of molecular epidemiology. This review summarizes data addressing the relationships of human lung cancer to polymorphisms of phase I procarcinogen-activating and phase II-deactivating enzymes and intermediate biomarkers of DNA mutation, such as DNA adducts, oncogene and tumor suppressor gene mutation, and polymorphisms. These parameters are reviewed as they relate to tobacco smoke exposure, procarcinogen metabolizing polymorphisms, and the presence of lung cancer. Problem areas in biomarker validation, such as cross-sectional data interpretation, tissue source, race, statistical power, and ethical implications are addressed.

KW - Biomarkers

KW - DNA adducts

KW - Lung cancer

KW - Oncogenes

KW - Phase I metabolism

KW - Phase II metabolism

KW - Susceptibility

KW - Tumor suppressor genes

UR - http://www.scopus.com/inward/record.url?scp=0030739591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030739591&partnerID=8YFLogxK

M3 - Article

C2 - 9263643

AN - SCOPUS:0030739591

VL - 27

SP - 319

EP - 365

JO - Critical Reviews in Toxicology

JF - Critical Reviews in Toxicology

SN - 1040-8444

IS - 4

ER -